Anti-tumor-promoting activity of diterpenes from Excoecaria agallocha

Biological and Pharmaceutical Bulletin

Volumn 21, Issue 9, 1998, Pages 993-996

  Konishi, Tenji ^a   Takasaki, Midori ^a   Tokuda, Harukuni ^b   Kiyosawa, Shu ^a   Konoshima, Takao ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Anti tumor promoter; Diterpene; Euphorbiaceae; Excoecaria agallocha; Two stage carcinogenesis

Indexed keywords

15 HYDROXY LABDA 8(17),13E DIEN 3 ONE; 16 HYDROXY 3 OXO 13 EPI MANOYLOXIDE; 3BETA HYDROXY 15 BEYEREN 2 ONE; 8ALPHA,13,14,15 DIEPOXY 13 EPI LABDA 3BETA OL; DITERPENE; EXCOECARIA AGALLOCHA EXTRACT; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ISOLATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; LIVER CARCINOMA; LUNG CARCINOMA; MOUSE; NONHUMAN; RAJI CELL; SKIN CARCINOMA; TOPICAL DRUG ADMINISTRATION; TRADITIONAL MEDICINE;

EID: 0031663402     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.21.993     Document Type: Article

References (20)

1. A part of this work was presented at the 118th Annual Meeting of the Japan Pharmaceutical Association, Kyoto, March, 1998, Abstracts Papers, p. 122.
2. Wiriyachitra P., Hajiwangoh H., Boonton P., Adolf W., Opferkuch H. J., Hecker E., Planta Med., 51, 368-371 (1985); Karalai C., Wiriyachitra P., Opferkuch H. J., Hecker E., ibid, 60, 351-355 (1994).
3. Wiriyachitra P., Hajiwangoh H., Boonton P., Adolf W., Opferkuch H. J., Hecker E., Planta Med., 51, 368-371 (1985); Karalai C., Wiriyachitra P., Opferkuch H. J., Hecker E., ibid, 60, 351-355 (1994).
4. Ohigashi H., Katsumata H., Kawazu K., Koshimizu K., Mitsui T., Agr. Biol. Chem., 38, 1093-1095 (1974).
5. Prakash S., Khan M.A., Khan H., Zaman A., Phytochemistry, 22, 1836-1837 (1983).
6. Kawashima T., Takahashi T., Inoue Y., Kodama M., Ito S., Phytochemistry, 10, 3308-3309 (1971).
7. Metcalfe C. R., Kew Bull., 1, 8-9 (1933).
8. Erickson K. L., Beutler J. A., Cardellina II. J. H., McMahon J. B., Newman D. J., Boyd M. R., J. Nat, Prod., 58, 769-772 (1995).
9. Konishi T., Azuma M., Itoga R., Kiyosawa S., Fujiwara Y., Shimada Y., Chem. Pharm. Bull., 44, 229-231 (1996); Konishi T., Kiyosawa S., Konoshima T., Fujiwara Y., ibid., 44, 2100-2102 (1996).
10. Konishi T., Azuma M., Itoga R., Kiyosawa S., Fujiwara Y., Shimada Y., Chem. Pharm. Bull., 44, 229-231 (1996); Konishi T., Kiyosawa S., Konoshima T., Fujiwara Y., ibid., 44, 2100-2102 (1996).
11. Konoshima T., Takasaki M., Kozuka M., Inada A., Nakanishi T., Tokuda H., Matsumoto T., Shouyakugaku Zasshi, 43, 135-141 (1989).
12. Takasaki M., Konoshima T., Kozuka M., Tokuda H., Biol. Pharm. Bull., 18, 435-438 (1995), and references cited therein.
13. Konoshima T., Takasaki M., Tokuda H., Masuda K., Arai Y., Shiojima K., Ageta H., Biol. Pharm. Bull., 19, 962-965 (1996), and references cited therein.
14. Konoshima T., Takasaki M., Tokuda H., Natural Medicines, 50, 158-162 (1996), and references cited therein.
15. Takasaki M., Konoshima T., Yasuda I., Hamano T., Tokuda H., Biol. Pharm. Bull., 20, 776-780 (1997).
16. The activation percentages of the acetone extract of E. agallocha on EBV-EA were only 2.9% and 0% at the concentrations of 100 μg/ml and 10 μg/ml, respectively. And, the inhibitory percentages of this extract on EBV-EA activation were 89.6% and 19.9% at 100 μg/ml and 10 μg/ml, respectively.
17. Henle G., Henle W., J. Bacteriol., 91, 1248-1265 (1966).
18. A high viability of Raji cells is necessary for in vitro assay using an indirect immunofluorescence technique by antigen-antibody reaction and is beneficial for the following in vivo assay.
19. Ohigashi H., Takamura H., Koshimizu K., Tokuda H., Ito Y., Cancer Lett., 30, 143-146 (1986).
20. 2 and 1×10mol ratio/TPA, respectively, and the viability percentage of Raji cells was more than 80% at each concentration; Mizutani K., Kuramoto T., Tamura K., Kozuka M., Tokuda H., Abstracts of Papers, the 113th Annual Meeting of the Pharmaceutical Society of Japan, Osaka, March 1993, Part II, p. 206.